vTv Therapeutics Inc
NASDAQ:VTVT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
vTv Therapeutics Inc
Cash from Financing Activities
vTv Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
Cash from Financing Activities
$77.4m
|
CAGR 3-Years
74%
|
CAGR 5-Years
32%
|
CAGR 10-Years
-5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$12.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$7.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$10.9B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$2.3B
|
CAGR 3-Years
-222%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$3.7B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-30%
|
|
vTv Therapeutics Inc
Glance View
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 9 full-time employees. The company went IPO on 2015-07-30. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non- central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Nrf2/Bach1 Modulator Program.
See Also
What is vTv Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
77.4m
USD
Based on the financial report for Dec 31, 2025, vTv Therapeutics Inc's Cash from Financing Activities amounts to 77.4m USD.
What is vTv Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-5%
Over the last year, the Cash from Financing Activities growth was 47%. The average annual Cash from Financing Activities growth rates for vTv Therapeutics Inc have been 74% over the past three years , 32% over the past five years , and -5% over the past ten years .
